Genmab and J&J 'love' partnership as some ponder takeover

LONDON (Reuters) – Genmab was Europe’s second biggest biotech company, until its partner Johnson & Johnson bought Switzerland’s Actelion for $30 billion this year and propelled the Danish antibody specialist to the top spot.

Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *